Prescription medication · MAO-B Inhibitor

safinamide

Also sold as Xadago. Safinamide is used to treat Parkinson's disease.

Data updated 2026-05-15

1,205
FDA reportsRarely reported
10
InteractionsSeveral interactions
$36.56
Brand price (NADAC)

What the data shows

safinamide (Xadago) is a prescription MAO-B Inhibitor, among the least-reported drugs the FDA tracks (1,205 FDA reports), with 10 documented drug interactions.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

safinamide (Xadago) is a prescription MAO-B Inhibitor. Safinamide is used to treat Parkinson's disease.

Safinamide (Xadago) is a drug used with levodopa/carbidopa to treat Parkinson's disease. It helps reduce "off" episodes, where symptoms like stiffness and slowness return.

Drug Pricing (NADAC)

Brand Price

$36.56/unit

Generic Available

No

MDD US

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

View Alternatives → Compare with Another Drug → Full Side Effects Report →

What it does

Safinamide is used to treat Parkinson's disease.

Common side effects

Uncontrolled movements (dyskinesia), Falls, Feeling sick to your stomach (nausea)

Key warnings

Safinamide can cause or worsen high blood pressure.

The sections below are summarized in plain English from safinamide's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Safinamide is a MAO-B inhibitor. It works by blocking an enzyme in the brain that breaks down dopamine. This helps increase the amount of dopamine available, which can improve motor control.

Side Effects (from patient reports)

Based on 1,205 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for safinamide, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for safinamide each year to the FDA Adverse Event Reporting System (FAERS).

050100150200 2016201720182019202020212022202320242025 164

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where safinamide sits

safinamide has more FDA adverse-event reports than 8% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is safinamide; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 1,205 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2016–2025.

Total Reports

1,205

Reports Mentioning Death

151

12.5% of reports — not proof of cause

Hospitalization Reports

496

Top Indication

Parkinson^S Disease

Gender Distribution

Female 456 (41%)
Male 648 (59%)

Age Distribution

0–17 2
18–44 10
45–64 143
65–74 330
75+ 324

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 FALL 154
2 HALLUCINATION 142
3 DYSKINESIA 137
4 GAIT DISTURBANCE 93
5 DEATH 90
6 PARKINSON^S DISEASE 89
8 TREMOR 81
9 FATIGUE 76
10 FREEZING PHENOMENON 74
11 ON AND OFF PHENOMENON 72
12 SOMNOLENCE 64
13 ANXIETY 61
14 NAUSEA 60
15 DIZZINESS 56
16 WEIGHT DECREASED 54

Reactions in Death Reports

DEATH 90
GENERAL PHYSICAL HEALTH DETERIORATION 16
PARKINSON^S DISEASE 12
FALL 11
VOMITING 9
DYSKINESIA 8
EPILEPSY 7
MYOCARDIAL INFARCTION 7
DYSPHAGIA 6
HALLUCINATION 6

Reactions in Hospitalization Reports

FALL 107
HALLUCINATION 69
DYSKINESIA 61
PARKINSON^S DISEASE 39
ON AND OFF PHENOMENON 38
GAIT DISTURBANCE 37
HYPERKINESIA 33
GENERAL PHYSICAL HEALTH DETERIORATION 31
WEIGHT DECREASED 31
MOBILITY DECREASED 30

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Safinamide can cause or worsen high blood pressure. It can also cause serotonin syndrome, a dangerous condition, if taken with certain other medicines. Some people taking safinamide have fallen asleep suddenly during normal activities. Safinamide may also cause or worsen uncontrolled movements, hallucinations, and compulsive behaviors. Stopping safinamide suddenly can cause serious withdrawal symptoms.

Known Drug Interactions

7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2) ] .

Mechanism: Combining these drugs can cause a dangerous buildup of serotonin in the brain, which may lead to a life-threatening reaction.

Concomitant use of XADAGO with methylphenidate, amphetamine, and their derivatives is contraindicated [see Warnings and Precautions (5.1 , 5.2) ] .

Mechanism: These drugs both increase certain brain chemicals that can cause your blood pressure to rise to dangerous levels.

7 DRUG INTERACTIONS Selective Serotonin Reuptake Inhibitors: Monitor patients for serotonin syndrome ( 7.3 ) Sympathomimetic Medications: Monitor patients for hypertension ( 7.5 ) Tyramine: Risk of severe hypertension ( 7.6 ) 7.1 MAO Inhibitors (MAOIs) XADAGO is contraindicated for use with other drugs in the MAOIs class or other drugs that are potent inhibitors of monoamine oxidase (e.g., linezolid, an oxazolidinone antibacterial, which also has reversible nonselective MAO inhibition activity).

Mechanism: Both drugs stop the body from breaking down certain chemicals, which can lead to a toxic buildup in your system.

7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2) ] .

Mechanism: Taking these together can cause a very serious and potentially fatal reaction in the brain and nervous system.

7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2) ] .

Mechanism: This combination can cause a severe, life-threatening reaction by interfering with how the brain handles certain chemicals.

Check all your medications →

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

Can I take safinamide if I have liver problems?
If you have moderate liver problems, your doctor may prescribe a lower dose (50 mg). If you have severe liver problems, you should not take safinamide.
Can I eat whatever I want while taking safinamide?
You don't need to avoid most foods. However, avoid foods with very high amounts of tyramine (over 150mg), as this could cause dangerously high blood pressure.
What should I do if I experience side effects?
Tell your doctor about any side effects you experience while taking safinamide.
Can I take safinamide with my other Parkinson's medications?
Safinamide is meant to be taken with levodopa/carbidopa. Talk to your doctor about all the medications you are taking.
How long does it take for safinamide to start working?
It may take a few weeks to see the full effects of safinamide. Talk to your doctor if you don't notice any improvement.
Can safinamide cause high blood pressure?
Yes, safinamide can cause or worsen high blood pressure. Your doctor will monitor your blood pressure.
What if I want to stop taking safinamide?
Talk to your doctor before stopping safinamide. You may need to lower the dose slowly to avoid withdrawal symptoms.
Can safinamide cause me to fall asleep suddenly?
Yes, safinamide can cause some people to fall asleep suddenly, even during normal activities. Be careful when driving or operating machinery.
Is safinamide a cure for Parkinson's disease?
No, safinamide does not cure Parkinson's disease. It helps manage the symptoms.
Are there any foods I should avoid while taking safinamide?
Avoid foods containing very high amounts of tyramine, such as aged cheeses and cured meats.
What are the common side effects of safinamide?
The registry lists Uncontrolled movements (dyskinesia), Falls, Feeling sick to your stomach (nausea), Trouble sleeping (insomnia) among the most-reported FAERS reaction terms for safinamide. The compiled record contains 1,205 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does safinamide interact with other medications?
The registry has 10 documented interaction rows for safinamide. Notable source-record pairings include tramadol, methylphenidate, linezolid. These rows are not a complete medication review.
What drug class is safinamide?
safinamide belongs to the MAO-B Inhibitor drug class. It requires a prescription (Rx). Safinamide is used to treat Parkinson's disease.
What pregnancy or breastfeeding source fields are listed for safinamide?
The FDA label for safinamide contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Other drugs grouped near safinamide - same-class peers and common alternatives.

Compare safinamide vs acamprosate side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for safinamide: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

Save on safinamide

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for safinamide

The FDA label for safinamide (sold under brand names such as Xadago) classifies it as a prescription-only medication in the MAO-B Inhibitor class. Safinamide is used to treat Parkinson's disease. Official labeling lists 4 commonly reported side effects, including Uncontrolled movements (dyskinesia), Falls, Feeling sick to your stomach (nausea).

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,205 voluntary reports. The database also lists 10 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: October 22, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page